Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
The Breakthrough Therapy Designation is based on encouraging results from the Phase 2 TROPiCS-03 study of Trodelvy as a second-line treatment for ES-SCLC.
Trodelvy is currently approved in more than 40 countries for multiple types of breast cancer. The drug is also approved for the treatment of urothelial cancer in many countries.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.